| Peripheral T cell expansion predicts tumour infiltration and clinical response TD Wu, S Madireddi, PE de Almeida, R Banchereau, YJJ Chen, AS Chitre, ... Nature 579 (7798), 274-278, 2020 | 523 | 2020 |
| TNF superfamily in inflammatory disease: translating basic insights M Croft, W Duan, H Choi, SY Eun, S Madireddi, A Mehta Trends in immunology 33 (3), 144-152, 2012 | 301 | 2012 |
| High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade KC Yuen, LF Liu, V Gupta, S Madireddi, S Keerthivasan, C Li, ... Nature medicine 26 (5), 693-698, 2020 | 290 | 2020 |
| Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies S Madireddi, SY Eun, SW Lee, I Nemčovičová, AK Mehta, DM Zajonc, ... Journal of Experimental Medicine 211 (7), 1433-1448, 2014 | 146 | 2014 |
| Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade R Banchereau, AS Chitre, A Scherl, TD Wu, NS Patil, P de Almeida, ... Journal for ImmunoTherapy of Cancer 9 (4), 2021 | 89 | 2021 |
| Targeting CD4+ CD25+ FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. RH Schabowsky, S Madireddi, R Sharma, ES Yolcu, H Shirwan Current Opinion in Investigational Drugs (London, England: 2000) 8 (12 …, 2007 | 81 | 2007 |
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines RK Sharma, RH Schabowsky, AK Srivastava, KG Elpek, S Madireddi, ... Cancer research 70 (10), 3945-3954, 2010 | 68 | 2010 |
| A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity RH Schabowsky, KG Elpek, S Madireddi, RK Sharma, ES Yolcu, ... Vaccine 28 (2), 512-522, 2009 | 67 | 2009 |
| SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ S Madireddi, RH Schabowsky, AK Srivastava, RK Sharma, ES Yolcu, ... Public Library of Science 7 (8), e42459, 2012 | 58 | 2012 |
| Regulatory T cell–mediated suppression of inflammation induced by DR3 signaling is dependent on galectin-9 S Madireddi, SY Eun, AK Mehta, A Birta, DM Zajonc, T Niki, M Hirashima, ... The Journal of Immunology 199 (8), 2721-2728, 2017 | 51 | 2017 |
| SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model RK Sharma, AK Srivastava, ES Yolcu, KJ MacLeod, RH Schabowsky, ... Vaccine 28 (36), 5794-5802, 2010 | 51 | 2010 |
| Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1 S Keerthivasan, Y Şenbabaoğlu, N Martinez-Martin, B Husain, ... Immunity 54 (7), 1511-1526. e8, 2021 | 48 | 2021 |
| CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy MA Huseni, L Wang, JE Klementowicz, K Yuen, B Breart, C Orr, L Liu, Y Li, ... Cell Reports Medicine 4 (1), 2023 | 45 | 2023 |
| Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. MC Seung-Woo Lee, Yunji Park, So-Young Eun, Shravan Madireddi, Hilde Cheroutre The Journal of Immunology, 2012 | 44 | 2012 |
| High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA SA Oh, K Senger, S Madireddi, I Akhmetzyanova, IE Ishizuka, S Tarighat, ... Journal of Experimental Medicine 219 (5), 2022 | 37 | 2022 |
| Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members Y Yang, SH Yeh, S Madireddi, WL Matochko, C Gu, P Pacheco Sanchez, ... MAbs 11 (6), 996-1011, 2019 | 32 | 2019 |
| Modulators of 4-1bb and immune responses M Croft, S Madireddi US Patent App. 14/127,134, 2014 | 22 | 2014 |
| In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales J Chen, S Madireddi, D Nagarkar, M Migdal, J Vander Heiden, D Chang, ... Briefings in Bioinformatics 22 (3), bbaa223, 2021 | 20 | 2021 |
| ProtEx™ technology for the generation of novel therapeutic cancer vaccines RH Schabowsky, RK Sharma, S Madireddi, A Srivastava, ES Yolcu, ... Experimental and molecular pathology 86 (3), 198-207, 2009 | 14 | 2009 |
| Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade KC Yuen, LF Liu, V Gupta, S Madireddi, S Keerthivasan, C Li, ... Nature Medicine 27 (3), 560-560, 2021 | 5 | 2021 |
Haval ShirwanUniversity of Missouri, Columbia在 health.missouri.edu 的电子邮件经过验证
